RYTM
Rhythm Pharmaceuticals, Inc.
37.80
USD
This page is just a preview of the data found in TrendSpider’s full version
Rhythm Pharmaceuticals, Inc. stock is up 39.53% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 71.43% of the previous 6 December’s closed higher than November. In the last 8 Unusual Options Trades, there were 5 CALLs, 3 PUTs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 19 Oct 15:20 | 15 Dec, 2023 | 25.00 | 920 | ||
| 19 Oct 15:21 | 15 Dec, 2023 | 25.00 | 920 | ||
| 13 Nov 14:56 | 19 Jan, 2024 | 30.00 | 0 | ||
| 17 Nov 20:18 | 15 Dec, 2023 | 40.00 | 3 | ||
| 04 Dec 15:46 | 19 Jul, 2024 | 17.50 | 80 | ||
| 05 Dec 14:30 | 15 Dec, 2023 | 30.00 | 290 | ||
| 05 Dec 17:55 | 19 Apr, 2024 | 40.00 | 1 | ||
| 05 Dec 20:59 | 19 Apr, 2024 | 40.00 | 1 |
Rhythm Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency.
